SCHEMBL18838379

SCHEMBL18838379

CC(C)(C)OC(=O)N1CCC2(CCC2NCc2ccccc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ STS P08842 1/20 0.51
▸ KEAP1 Q14145 1/20 0.51
▸ NFE2L2 Q16236 1/20 0.51
▸ NAMPT P43490 1/20 0.50
▸ GPR119 Q8TDV5 2/20 0.48
▸ KDM4E B2RXH2 1/20 0.48
▸ PKM P14618 1/20 0.48
▸ LMNA P02545 1/20 0.48
▸ ACHE P22303 1/20 0.48
▸ OPRD1 P41143 1/20 0.46
▸ OPRK1 P41145 1/20 0.46
▸ KDM1A O60341 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.45
▸ TP53 P04637 1/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ TSHR P16473 1/20 0.44
▸ ATM Q13315 1/20 0.44
▸ TACR1 P25103 1/20 0.44
▸ GAA P10253 1/20 0.44
▸ THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18838507 0.94 KEAP1 (0.49) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL18838508 0.87 NAMPT (0.46) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL18838380 0.87 NAMPT (0.46) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL15601289 0.83 KEAP1 (0.46) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL19995750 0.83 STS (0.48) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL16054997 0.82 KEAP1 (0.53) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL16914194 0.82 ALDH1A1 (0.51) STSNAMPTGPR119LMNATP53
SCHEMBL616004 0.81 STS (0.60) STSKEAP1NFE2L2GPR119KDM4E
SCHEMBL21397614 0.81 KDM1A (0.56) STSKEAP1NFE2L2NAMPTGPR119
SCHEMBL18498090 0.81 KEAP1 (0.49) STSKEAP1NFE2L2NAMPTGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 — — EP disclosed
CN-108289886-B Ion channel inhibiting compounds, pharmaceutical formulations and uses 安华赛公司 2022-01-28 — — CN disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses AFASCI, INC. (US) 2020-02-18 — — US disclosed
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses AFASCI, INC. (US) 2018-11-01 — — US disclosed
EP-3340988-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES Afasci, Inc. (US) 2018-07-04 — — EP disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed
WO-2017083867-A1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI, INC. (US) 2017-05-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10562857-B2 Ion channel inhibitory compounds, pharmaceutical formulations, and uses CACNA1I, CACNA1G, CACNA1H STS 4220/4885KEAP1 3501/4885NFE2L2 3679/4885
US-20180312471-A1 Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses CACNA1I, CACNA1G, CACNA1H STS 4220/4885KEAP1 3501/4885NFE2L2 3679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback